A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Gattenlohner S ^a   Jorissen H ^b   Huhn, M ^c   Vincent, A ^c   Beeson, D ^d   Tzartos, S ^d   Mamalaki, A ^a   Etschmann, B ^a   Muller Hermelink, H K ^a   Koscielniak, E ^e   Barth, S ^a,f   Marx, A ^a,g  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HELLENIC PASTEUR INSTITUTE   (Greece)

^e OLGAHOSPITAL   (Germany)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EMBRYO CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR VOLUME;

MURINAE; PSEUDOMONAS EXOTOXIN;

EID: 84858645667     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/187621     Document Type: Article

References (64)

1. D. M. Parham and D. A. Ellison, "Rhabdomyosarcomas in adults and children: an update," Archives of Pathology and Laboratory Medicine, vol. 130, no. 10, pp. 1454-1465, 2006. (Pubitemid 44520712)
2. E. Koscielniak, M. Morgan, and J. Treuner, "Soft tissue sarcoma in children: prognosis and management," Pediatric Drugs, vol. 4, no. 1, pp. 21-28, 2002. (Pubitemid 34208343)
3. R. B. Raney, J. R. Anderson, F. G. Barr, et al., "Rhabdomyosar-coma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosar-coma study V," Journal of Pediatric Hematology/Oncology, vol. 23, no. 4, pp. 215-220, 2001. (Pubitemid 32524925)
4. L. M. Smith, J. R. Anderson, and C. M. Coffin, "Cytodifferen-tiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS)," Medical and Pediatric Oncology, vol. 38, pp. 398-404, 2002. (Pubitemid 34507283)
5. M. Carli, R. Colombatti, O. Oberlin, et al., "European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors," Journal of Clinical Oncology, vol. 22, no. 23, pp. 4735-4742, 2004. (Pubitemid 41185090)
6. S. Gattenloehner, A. Vincent, I. Leuschner, et al., "The fetal form of the acetylcholine receptor distinguishes rhab-domyosarcomas from other childhood tumors," American Journal of Pathology, vol. 152, no. 2, pp. 437-444, 1998. (Pubitemid 28106390)
7. S. Gattenlöhner, B. Dockhorn-Dworniczak, I. Leuschner, et al., "A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas," Journal of Molecular Diagnostics, vol. 1, no. 1, pp. 23-31, 1999. (Pubitemid 129693358)
8. S. Gattenlöhner, H. K. Muller-Hermelink, and A. Marx, "Poly-merase chain reaction-based diagnosis of rhabdomyosarco-mas: comparison of fetal type acetylcholine receptor subunits and myogenin," Diagnostic Molecular Pathology, vol. 7, no. 3, pp. 129-134, 1998. (Pubitemid 28533552)
9. S. Gattenlöhner, A. Marx, B. Markfort, et al., "Rhabdomyosar- coma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor," Cancer Research, vol. 66, no. 1, pp. 24-28, 2006. (Pubitemid 43166003)
10. D. L. Siegel, "Recombinant monoclonal antibody technology," Transfusion Clinique et Biologique, vol. 9, no. 1, pp. 15-22, 2002. (Pubitemid 34151637)
11. K. Oda, "Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers," Annals of the New York Academy of Sciences, vol. 681, pp. 238-255, 1993. (Pubitemid 23233826)
12. S. Khanna, C. R. Richmonds, H. J. Kaminski, and J. D. Porter, "Molecular organization of the extraocular muscle neuromus-cular junction: partial conservation of and divergence from the skeletal muscle prototype," Investigative Ophthalmology and Visual Science, vol. 44, no. 5, pp. 1918-1926, 2003. (Pubitemid 36520280)
13. H. J. Kaminski and R. L. Ruff, "Ocular muscle involvement by myasthenia gravis," Annals of Neurology, vol. 41, no. 4, pp. 419-420, 1997. (Pubitemid 27169178)
14. M. Schluep, N. Willcox, A. Vincent, G. K. Dhoot, and J. Newsom-Davis, "Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study," Annals of Neurology, vol. 22, pp. 212-222, 1987. (Pubitemid 17131152)
15. T. Kirchner, S. Tzartos, F. Hoppe, et al., "Pathogenesis of myasthenia gravis: acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors," American Journal of Pathology, vol. 130, no. 2, pp. 268-280, 1988. (Pubitemid 18076361)
16. K. I. Geuder, A. Marx, V. Witzemann, et al., "Pathogenetic significance of fetal-type acetylcholine receptors on thymic myoid cells in myasthenia gravis," Developmental Immunology, vol. 2, no. 2, pp. 69-75, 1992.
17. H. R. Brenner, V. Witzemann, and B. Sakmann, "Imprinting of acetylcholine receptor messenger RNA accumulation in mammalian neuromuscular synapses," Nature, vol. 344, no. 6266, pp. 544-546, 1990. (Pubitemid 20124431)
18. S. Gattenlöhner, C. Schneider, C. Thamer, et al., "Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders," Brain, vol. 125, no. 6, pp. 1309-1319, 2002. (Pubitemid 34587140)
19. A. Vincent, J. McConville, M. E. Farrugia, et al., "Antibodies in myasthenia gravis and related disorders," Annals of the New York Academy of Sciences, vol. 998, pp. 324-335, 2003. (Pubitemid 37194175)
20. C. B. Weinberg and Z. W. Hall, "Junctional form of acetyl-cholinesterase restored at nerve-free endplates," Developmental Biology, vol. 68, no. 2, pp. 631-635, 1979. (Pubitemid 9113082)
21. I. Matthews, G. Sims, S. Ledwidge, et al., "Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen," Laboratory Investigation, vol. 82, no. 10, pp. 1407-1417, 2002. (Pubitemid 35191544)
22. P. Tsantili, S. J. Tzartos, and A. Mamalaki, "High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor," Journal of Neuroimmunology, vol. 94, no. 1-2, pp. 15-27, 1999. (Pubitemid 29071239)
23. S. Tzartos, L. Langeberg, S. Hochschwender, and J. Lindstrom, "Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor," FEBS Letters, vol. 158, no. 1, pp. 116-118, 1983. (Pubitemid 13011920)
24. L. Daniel, P. Durbec, E. Gautherot, et al., "A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process," Oncogene, vol. 20, no. 8, pp. 997-1004, 2001. (Pubitemid 32207117)
25. C. A. Hudis, "Trastuzumab-mechanism of action and use in clinical practice," The New England Journal of Medicine, vol. 357, pp. 39-51, 2007. (Pubitemid 47026733)
26. A. Engert, C. Gottstein, U. Winkler, et al., "Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins," Leukemia and Lymphoma, vol. 13, no. 5-6, pp. 441-448, 1994. (Pubitemid 24158964)
27. A. Engert, C. Gottstein, U. Winkler, et al., "New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?" Medizinische Klinik, vol. 87, no. 10, pp. 503-509, 1992.
28. M. Huhn, S. Sasse, M. K. Tur, et al., "Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cyto-toxicity against CD30-positive lymphoma," Cancer Research, vol. 61, no. 24, pp. 8737-8742, 2001. (Pubitemid 34013885)
29. M. K. Tur, I. Neef, E. Jost, et al., "Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in hodgkin lymphoma cells," Journal of Immunotherapy, vol. 32, no. 5, pp. 431-441, 2009.
30. M. K. Tur, I. Neef, G. Jäger, et al., "Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy," Current Pharmaceutical Design, vol. 15, no. 23, pp. 2693-2699, 2009.
31. M. K. Tur, M. Huhn, T. Thepen, et al., "Recombinant CD64-specific single chain Immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells," Cancer Research, vol. 63, no. 23, pp. 8414-8419, 2003. (Pubitemid 37549497)
32. B. Stahnke, T. Thepen, M. Stöcker, et al., "Granzyme BH22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukaemia of monocyte subtypes," Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2924-2932, 2008.
33. C. Hetzel, C. Bachran, R. Fischer, H. Fuchs, S. Barth, and M. Stöcker, "Small cleavable adapters enhance the specific cyto-toxicity of a humanized immunotoxin against CD64-positive acute myeloid leukemia cells," Journal of Immunotherapy, vol. 31, no. 4, pp. 370-376, 2008. (Pubitemid 351595159)
34. C. Di Paolo, J. Willuda, S. Kubetzko, et al., "A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity," Clinical Cancer Research, vol. 9, no. 7, pp. 2837-2848, 2003. (Pubitemid 36842130)
35. P. J. O'Dwyer and A. B. Benson, "3rd epidermal growth factor receptor-targeted therapy in colorectal cancer," Seminars in Oncology, vol. 29, pp. 10-17, 2002. (Pubitemid 35191042)
36. D. Fan, S. Yano, H. Shinohara, et al., "Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin," Molecular Cancer Therapeutics, vol. 1, no. 8, pp. 595-600, 2002.
37. V. A. Pollack, E. Alvarez, K. F. Tse, et al., "Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB," Cancer Chemotherapy and Pharmacology, vol. 60, no. 3, pp. 423-435, 2007. (Pubitemid 46944592)
38. M. K. Tur, S. Sasse, M. Stöcker, et al., "An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neurob-lastoma derived cell lines," International Journal of Molecular Medicine, vol. 8, no. 5, pp. 579-584, 2001.
39. O. Manzke, O. Russello, C. Leenen, et al., "Immunother-apeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies," Medical and Pediatric Oncology, vol. 36, pp. 185-189, 2001.
40. C. Gottstein, G. Schon, S. Tawadros, et al., "Antidisialogan- glioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model," Cancer Research, vol. 54, no. 23, pp. 6186-6193, 1994. (Pubitemid 24980122)
41. C. Rossig, S. Pscherer, S. Landmeier, et al., "Adoptive cellular immunotherapy with CD19-specific T cells," Klinische Padia-trie, vol. 217, no. 6, pp. 351-356, 2005. (Pubitemid 41746118)
42. Y. F. Graus, M. H. De Baets, P. W. H. I. Parren, et al., "Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies," Journal of Immunology, vol. 158, no. 4, pp. 1919-1929, 1997. (Pubitemid 127469552)
43. J. Farrar, S. Portolano, N. Willcox, et al., "Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library," International Immunology, vol. 9, no. 9, pp. 1311-1318, 1997. (Pubitemid 27389013)
44. H. N. Lode, T. Moehler, R. Xiang, et al., "Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 4, pp. 1591-1596, 1999. (Pubitemid 29098496)
45. S. J. Tzartos, T. Barkas, M. T. Cung, et al., "Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor," Immunological Reviews, vol. 163, pp. 89-120, 1998. (Pubitemid 28327864)
46. C. A. Pennell and H. A. Erickson, "Designing immunotoxins for cancer therapy," Immunologic Research, vol. 25, no. 2, pp. 177-191, 2002. (Pubitemid 34264103)
47. T. K. Bera, J. Williams-Gould, R. Beers, P. Chowdhury, and I. Pastan, "Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer," Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 79-84, 2001.
48. J. Thompson, S. Stavrou, M. Weetall, et al., "Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion," Protein Engineering, vol. 14, no. 12, pp. 1035-1041, 2001. (Pubitemid 34137244)
49. T. Decker, S. Hipp, R. J. Kreitman, et al., "Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides," Blood, vol. 99, no. 4, pp. 1320-1326, 2002. (Pubitemid 34547087)
50. H. Matsui, A. Takeshita, K. Naito, et al., "Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers," Leukemia, vol. 16, no. 5, pp. 813-819, 2002. (Pubitemid 34537552)
51. T. A. Jarvinen and E. T. Liu, "Topoisomerase IIα gene (TOP2A) amplification and deletion in cancer-more common than anticipated," Cytopathology, vol. 14, no. 6, pp. 309-313, 2003. (Pubitemid 37521860)
52. T. A. H. Järvinen and E. T. Liu, "HER-2/neu and topoiso-merase IIα-simultaneous drug targets in cancer," Combinatorial Chemistry and High Throughput Screening, vol. 6, no. 5, pp. 455-470, 2003. (Pubitemid 36944254)
53. T. A. Jarvinen and E. T. Liu, "HER-2/neu and topoisomerase IIα in breast cancer," Breast Cancer Research and Treatment, vol. 78, no. 3, pp. 299-311, 2003.
54. J. R. Fitzgerald, S. D. Reid, E. Ruotsalainen, et al., "Genome diversification in Staphylococcus aureus: molecular evolution of a highly variable chromosomal region encoding the staphylococcal exotoxin-like family of proteins," Infection and Immunity, vol. 71, no. 5, pp. 2827-2838, 2003. (Pubitemid 36519897)
55. M. S. McGrath, M. G. Rosenblum, M. R. Philips, and D. A. Scheinberg, "Immunotoxin resistance in multidrug resistant cells," Cancer Research, vol. 63, no. 1, pp. 72-79, 2003. (Pubitemid 36070422)
56. R. B. Walter, B. W. Raden, T. C. Hong, et al., "Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells," Blood, vol. 102, no. 4, pp. 1466-1473, 2003. (Pubitemid 36988058)
57. J. M. Ruehlmann, R. Xiang, A. G. Niethammer, et al., "MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma," Cancer Research, vol. 61, pp. 8498-8503, 2001. (Pubitemid 33131131)
58. R. Niv, Y. G. Assaraf, D. Segal, E. Pirak, and Y. Reiter, "Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein," International Journal of Cancer, vol. 94, pp. 864-872, 2001. (Pubitemid 33032836)
59. M. G. Rosenblum, L. Cheung, S. K. Kim, et al., "Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells," Cancer Immunology Immunotherapy, vol. 42, no. 2, pp. 115-121, 1996. (Pubitemid 26111179)
60. T. Kirchner, K. I. Geuder, A. Marx, and H. K. Muller-Hermelink, "Nicotinic acetylcholine receptors in tumors with rhabdomyomatous differentiation. Immunohistochem-ical amd molecular genetic demonstration," Verhandlungen der Deutschen Gesellschaft fur Pathologie, vol. 74, pp. 409-414, 1990.
61. S. Gattenlöhner, E. B. Brocker, and H. K. Muller-Hermelink, "Malignant melanoma with metastatic rhabdomyosarco-matoid transdifferentiation," The New England Journal of Medicine, vol. 358, no. 6, pp. 649-650, 2008. (Pubitemid 351214310)
62. S. Barth, M. Huhn, B. Matthey, A. Klimka, E. A. Galinski, and A. Engert, "Compatible solute-supported periplasmic expression of functional recombinant proteins under stress conditions," Applied and Environmental Microbiology, vol. 66, no. 4, pp. 1572-1579, 2000. (Pubitemid 30185634)
63. + Hodgkinderived cell lines," International Journal of Molecular Medicine, vol. 1, pp. 249-256, 1998.
64. D. R. Galloway, R. C. Hedstrom, and O. R. Pavlovskis, "Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa," Infection and Immunity, vol. 44, pp. 262-267, 1984. (Pubitemid 14139788)